Lineage Cell Therapeutics Inc
F:BT3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Lineage Cell Therapeutics Inc
F:BT3
|
US |
|
China Evergrande New Energy Vehicle Group Ltd
HKEX:708
|
HK |
|
B
|
Begistics PCL
SET:B
|
TH |
|
Encore Capital Group Inc
NASDAQ:ECPG
|
US |
|
V
|
Vimi Fasteners SpA
MIL:VIM
|
IT |
|
D
|
DOD Biotech PCL
SET:DOD
|
TH |
|
B
|
Bank Pan Indonesia Tbk PT
XMUN:PTQ
|
ID |
|
V
|
Vereinigte Filzfabriken AG
XMUN:VFF
|
DE |
|
S
|
Siam Steel International PCL
SET:SIAM
|
TH |
|
L
|
L'Air Liquide Societe Anonyme pour l'Etude et l'Exploitation des Procedes Georges Claude SA
XMUN:AIL
|
FR |
Intrinsic Value
Is BT3 undervalued or overvalued?
See the intrinsic value estimate for Lineage Cell Therapeutics Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Lineage Cell Therapeutics Does
Lineage Cell Therapeutics is a biotechnology company that develops cell-based medicines, with a focus on using living cells to replace or repair damaged tissue. Its main work is in regenerative medicine, especially programs for eye disease and spinal cord-related conditions. The company does not sell consumer products; it sells science, drug candidates, and development rights that could become future treatments.
- Headquarters
- United States of America US
- Employees
- 75
- IPO date
- Mar 5, 1992
Earnings Waterfall
Lineage Cell Therapeutics Inc
The intrinsic value for Lineage Cell Therapeutics Inc (BT3) under the Base Case is hidden EUR.
Compared with the current market price of 0.831 EUR, the stock appears hidden.